Larimar Therapeutics (LRMR) Profit After Tax (2013 - 2025)
Larimar Therapeutics (LRMR) posted Profit After Tax of -$62.5 million for Q4 2025, down 30.99% on a QoQ basis from -$47.7 million in Q3 2025, and down 117.33% year-over-year from $360.6 million in Q4 2024.
Larimar Therapeutics (LRMR) Profit After Tax (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at -$62.5 million for Q4 2025.
- Quarterly Profit After Tax fell 117.33% year-over-year to -$62.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$165.7 million (down 105.71% YoY) and the FY2025 annual result came in at -$165.7 million, down 105.71% from the prior year.
- Profit After Tax was -$62.5 million for Q4 2025 at Larimar Therapeutics, down from -$47.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$6.5 million in Q1 2023 and bottomed at -$62.5 million in Q4 2025.
- A 5-year average of -$18.5 million and a median of -$12.8 million in 2021 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2021 — Profit After Tax plunged 1680600.0% — and 2022, when it surged 50.49%.
- Larimar Therapeutics' Profit After Tax stood at -$9.1 million in 2021, then dropped by 3.05% to -$9.4 million in 2022, then slumped by 37.99% to -$13.0 million in 2023, then slumped by 121.33% to -$28.8 million in 2024, then slumped by 117.33% to -$62.5 million in 2025.
- Business Quant data shows LRMR's Profit After Tax at -$62.5 million in Q4 2025, -$47.7 million in Q3 2025, and -$26.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -62.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -62.50 Mn |
| Sep 30, 2025 | -47.71 Mn |
| Jun 30, 2025 | -26.18 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Dec 31, 2024 | -28.76 Mn |
| Sep 30, 2024 | -15.50 Mn |
| Jun 30, 2024 | -21.63 Mn |
| Mar 31, 2024 | -14.65 Mn |
| Dec 31, 2023 | -12.99 Mn |
| Sep 30, 2023 | -9.06 Mn |
| Jun 30, 2023 | -8.37 Mn |
| Mar 31, 2023 | -6.53 Mn |
| Dec 31, 2022 | -9.42 Mn |
| Sep 30, 2022 | -8.32 Mn |
| Jun 30, 2022 | -8.67 Mn |
| Mar 31, 2022 | -8.94 Mn |
| Dec 31, 2021 | -9.14 Mn |
| Sep 30, 2021 | -16.81 Mn |
| Jun 30, 2021 | -12.61 Mn |
| Mar 31, 2021 | -12.09 Mn |